Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional Health Outcomes

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional Health Outcomes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methylnaltrexone bromide (Primary)
  • Indications Constipation
  • Focus Therapeutic Use
  • Sponsors Pfizer; Progenics Pharmaceuticals; Salix Pharmaceuticals; Wyeth
  • Most Recent Events

    • 26 Oct 2022 Results of pooled analysis from two studies(n=363, study 302;NCT00402038; study 4000;NCT00672477) investigating if baseline patient characteristics impact the safety and efficacy of Methylnaltrexone for Opioid Induced Constipation in Patients With Advanced Illness presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
    • 22 Dec 2021 According to Bausch Health Companies media release, data from a post-hoc analysis (study 301, NCT00401362; study 302, NCT00402038; and study 4000, NCT00672477) supports the use of Salix s RELISTOR for patients with Opioid-Induced Constipation and advanced illness in the Emergency Department Setting
    • 22 Dec 2021 According to Bausch Health Companies media release, results assessing safety and efficacy of a single methylnaltrexone dose using post hoc polled data from 3 trials (study 301, NCT00401362; study 302, NCT00402038; and study 4000, NCT00672477) published in The Journal of Emergency Medicine
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top